Messi is awesome.

She's got a router. Shucks, she's even got a CNC machine.

Why even use the table saw to cut routers? To show off your German boobs?

A true enrichment of German culture. Bach, Beethoven, Goethe, Dschinghis Khan.

Interesting, I did not know that we have an embedded media plugin that can handle Daily Motion.

@George-K Goose/Gander.

It depends on how far they take it. I’d argue Waters’ encouraging confrontation of administration officials absolutely qualifies her for losing her seat.

But stripping someone of their seat for criticizing a foreign government? That’s not ok and is certainly not “goose/gander” material.

@lufins-dad said in What to tip?:

Don’t listen to @Mik , he’s too cheap to even send cookie packages…

Even at the cost of children starving from coast to coast.

@jolly said in She couldn't take Harry.:

In-breeding, lad, in-breeding...

FIFY

@mik said in Spuds...:

I can’t see bbq seasoning on potatoes.

Nor could I.

But, it works, surprisingly enough. Very little BBQ taste, if any.

Best piece I have read from him. My daughter found it.

https://www.newyorker.com/culture/culture-desk/stephen-sondheim-taught-me-how-to-be-a-person?fbclid=IwAR0xSaGwMBnC9HfwH7Ug4oV3kZzceGlhGx_sMPvKLBR3-HqLMcXciWGYEeQ

#2 looks photoshopped....

We haven't. Other than a brief stint in the first Gulf War and an even briefer stint during Gulf War II, our fighting has been mostly small unit, counter-insurgency and police-state work.

🤣

@lufins-dad said in Track the Vaxx:

@mik said in Track the Vaxx:

Short version: We don't know shit about breakthrough cases.

Color me shocked...

You don't even have to color me...

@jolly said in The Remains of the Day:

Have you repurposed your Thanksgiving day meal in any way?

@Aqua-Letifer is turning his into comedy act…

Would you like it to?

@lufins-dad said in What happened to all of the other vaccine development?:

Novavax has been close to filing

https://www.reuters.com/business/healthcare-pharmaceuticals/novavax-testing-vaccine-that-targets-new-covid-19-variant-2021-11-26/

Novavax Inc (NVAX.O) said on Friday it had started working on a version of its COVID-19 vaccine to target the variant detected in South Africa and would have the shot ready for testing and manufacturing in the next few weeks.

The company's COVID-19 shot contains an actual version of the virus' spike protein that cannot cause disease but can trigger the immune system. The vaccine developer said it had started developing a spike protein specifically based on the known genetic sequence of the variant, B.1.1.529.

"The initial work will take a few weeks," a company spokesperson said. Shares of the company closed up nearly 9% on Friday.

Novavax's vaccine received its first emergency use approval earlier this month in Indonesia followed by the Philippines.

The company has said it is on track to file for U.S. approval by the end of the year. It has also filed for approvals with the European Medicines Agency as well as in Canada.

Other vaccine developers, including Germany's BioNTech SE (22UAy.DE) and Johnson & Johnson (JNJ.N), have said they are testing the effectiveness of their shots against the new variant, which is named Omicron by the World Health Organisation. read more

Inovio Pharmaceuticals Inc (INO.O)said it had begun testing its vaccine candidate, INO-4800, to evaluate its effectiveness against the new variant. The company expects the testing to take about two weeks.

Inovio also said it was simultaneously designing a new vaccine candidate that specifically targeted Omicron.

"Best case scenario, INO-4800 ... will be completely resilient against omicron, but if that's not the case then we will have a newly designed vaccine ready to go if need be," said Kate Broderick, senior vice president of Inovio's R&D division.